Shots:

• BlueRock completes the 1st patient dosing in the P-I study of DA01 in patients with Parkinson's disease across the US & Canada. The program is currently recruiting & evaluating patients in an ongoing P-Ib study
• The 1EP of study is to assess safety & tolerability of DA01 cell transplantation @1yr. post-transplant & 2EPs are to assess the evidence of transplanted cell survival & motor effects @1/2 yrs. post-transplant and to evaluate safety & tolerability @2yrs. along with the feasibility of transplantation
• Bayer also initiates a gene therapy trial via AskBio in an ongoing P-Ib clinical study to assess the safety & preliminary efficacy of AVV gene therapy in 10 patients with PD in the US

  | Ref: Business Wire | Image: Business Standard